Illustration: Gabriella Turrisi/Axios
Topos Bio, a San Francisco-based biotech using AI to discover new medicines, raised a $10.5 million seed round, CEO Ryan Zarcone tells Axios Pro.
Why it matters: The company, which plans to raise its Series A later this year, is among a growing crop of drug developers seeking to harness AI.